Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the 2 GHSG NIVAHL trial

Tools

Item Type:	Letter
Title:	Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the 2 GHSG NIVAHL trial
Creators Name:	Robertz, Anne Sophie, Bühnen, Ina, Meissner, Julia, Trautmann-Grill, Karolin, Herhaus, Peter, Halbsguth, Teresa, Schaub, Valdete, Kerkhoff, Andrea, Mathas, Stephan, Bormann, Matthias, Dickhut, Andreas, Jaworek, Christian P., Fuchs, Michael, Kobe, Carsten, Baues, Christian, Borchmann, Peter, von Tresckow, Bastian, Behringer, Karolin and Bröckelmann, Paul J.
Abstract:	In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab and AVD (N-AVD) first-line treatment in the NIVAHL trial. These findings suggest preserved gonadal function and fertility following 4×N-AVD. NCT03004833.
Source:	Blood
ISSN:	0006-4971
Publisher:	American Society of Hematology / Elsevier
Date:	7 April 2026
Official Publication:	https://doi.org/10.1182/blood.2025031809
PubMed:	View item in PubMed

Repository Staff Only: item control page